아토피 피부염 치료제 시장 규모, 점유율, 성장 분석, 제품 유형별, 약제 클래스별, 치료법별, 투여 경로별, 유통별, 지역별 - 산업 예측(2025-2032년)
Atopic Dermatitis Drugs Market Size, Share, and Growth Analysis, By Product Type, By Drug Class, By Therapy, By Route of Administration, By Distribution, By Region - Industry Forecast 2025-2032
아토피 피부염 치료제 세계 시장 규모는 2023년 149억 1,000만 달러로 평가되었고, 예측 기간(2025-2032년) 동안 9.2%의 연평균 복합 성장률(CAGR)로 2024년 162억 8,000만 달러에서 2032년에는 329억 2,000만 달러로 성장할 것으로 예상됩니다.
2023년 10월 현재, 시장 인사이트에 따르면, 빠르게 진화하는 소비자 취향과 기술 발전에 적응하는 비즈니스에 대한 요구가 증가하고 있습니다. 데이터는 지속 가능한 관행으로 크게 변화하고 있으며, 소비자들은 환경적 책임을 우선시하는 브랜드를 점점 더 선호하고 있음을 보여줍니다. 또한, 기업들은 인공지능과 데이터 분석의 발전을 활용하여 고객 경험을 개선하기 위해 디지털 전환이 계속해서 중요한 초점이 되고 있습니다. 개인화된 제품 및 서비스에 대한 수요가 증가하면서 데이터 기반 전략을 통해 고객 행동을 이해하는 것이 중요하다는 점이 강조되고 있습니다. 경쟁 환경 분석에 따르면, 유연성과 시장 동향에 대한 대응력을 우선시하는 혁신적 기업은 성장에 유리한 위치에 있지만, 적응이 느린 기업은 시장 점유율을 유지하는 데 어려움을 겪을 수 있습니다. 전반적으로 민첩성과 지속가능성은 현재 시장을 형성하는 중요한 주제입니다.
목차
서론
조사 방법
- 정보 조달
- 2차와 1차 데이터 방법
- 시장 규모 예측
- 시장 전제조건과 제한
주요 요약
- 세계 시장 전망
- 공급과 수요 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porter의 Five Forces 분석
주요 시장 인사이트
- 중요 성공 요인
- 경쟁 정도
- 주요 투자 기회
- 시장 생태계
- 시장의 매력 지수(2024년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
- 규제 분석
아토피 피부염 치료제 시장 규모 : 제품 유형별
아토피 피부염 치료제 시장 규모 : 약제 클래스별
- 시장 개요
- 코르티코스테로이드
- 칼시뉴린 억제제
- PDE4 억제제
- 생물제제
- 기타
아토피 피부염 치료제 시장 규모 : 치료법별
- 시장 개요
- Photo Therapy
- Directed Therapy
아토피 피부염 치료제 시장 규모 : 투여 경로별
아토피 피부염 치료제 시장 규모 : 유통별
아토피 피부염 치료제 시장 규모
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
경쟁 정보
- 주요 5개사 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채택한 전략
- 최근 시장 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업 개요
- 기업 상세
- 제품 포트폴리오 분석
- 기업 부문별 점유율 분석
- 전년대비 매출 비교(2022-2024년)
주요 기업 개요
- Novartis AG(Switzerland)
- Pfizer Inc.(USA)
- Astellas Pharma Inc.(Japan)
- Bayer AG(Germany)
- Allergan plc(Ireland)
- Regeneron Pharmaceuticals, Inc.(USA)
- Sanofi S.A.(France)
- Incyte Corporation(USA)
- AbbVie Inc.(USA)
- Galderma S.A.(Switzerland)
- Leo Pharma A/S(Denmark)
- Eli Lilly and Company(USA)
- Amgen Inc.(USA)
- GlaxoSmithKline plc(UK)
- Johnson & Johnson(USA)
- Merck & Co., Inc.(USA)
- Takeda Pharmaceutical Company Limited(Japan)
- Bristol-Myers Squibb Company(USA)
- Almirall, S.A.(Spain)
- Sun Pharmaceutical Industries Ltd.(India)
결론과 제안
LSH
Global Atopic Dermatitis Drugs Market size was valued at USD 14.91 billion in 2023 and is poised to grow from USD 16.28 billion in 2024 to USD 32.92 billion by 2032, growing at a CAGR of 9.2% during the forecast period (2025-2032).
As of October 2023, market insights indicate a growing need for businesses to adapt to rapidly evolving consumer preferences and technological advancements. The data reveals a significant shift towards sustainable practices, with consumers increasingly favoring brands that prioritize environmental responsibility. Additionally, digital transformation remains a critical focus, as companies leverage advancements in artificial intelligence and data analytics to enhance customer experiences. The demand for personalized products and services is rising, emphasizing the importance of understanding customer behavior through data-driven strategies. Competitive landscape analysis suggests that innovative companies that prioritize flexibility and responsiveness to market trends are well-positioned for growth, while those lagging in adaptation may face challenges in retaining market share. Overall, agility and sustainability are key themes shaping the current marketplace.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Atopic Dermatitis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Atopic Dermatitis Drugs Market Segments Analysis
Global Atopic Dermatitis Drugs Market is segmented by Product Type, Drug Class, Therapy, Route of Administration, Distribution and region. Based on Product Type, the market is segmented into Biologics and Others. Based on Drug Class, the market is segmented into Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics and Others. Based on Therapy, the market is segmented into Photo Therapy and Directed Therapy. Based on Route of Administration, the market is segmented into Topical, Parenteral and Oral. Based on Distribution, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Other Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Atopic Dermatitis Drugs Market
The global market for atopic dermatitis drugs is anticipated to expand significantly due to the increasing incidence of this condition, which is attributed to factors such as environmental changes, urbanization, and genetic factors. As awareness of atopic dermatitis grows and its prevalence rises, particularly among children and young adults, the demand for effective treatments is expected to surge. This shift in demographics and the associated rise in cases highlight the urgent need for innovative drugs and therapies, driving market growth and development in the global healthcare landscape devoted to managing atopic dermatitis.
Restraints in the Global Atopic Dermatitis Drugs Market
The Global Atopic Dermatitis Drugs market faces significant challenges due to the side effects associated with certain treatments, raising concerns about long-term patient safety. Specifically, systemic immunosuppressants used for managing atopic dermatitis can lead to adverse effects, including increased susceptibility to infections and liver toxicity. These complications not only diminish patients' quality of life but also hinder the overall growth potential of the atopic dermatitis drugs market. As patients and healthcare providers weigh the risks versus benefits of these medications, the concerns surrounding safety could limit their widespread adoption and dampen market expansion.
Market Trends of the Global Atopic Dermatitis Drugs Market
The Global Atopic Dermatitis Drugs market is poised for significant growth through 2031, driven largely by the increasing adoption of JAK inhibitors such as upadacitinib and abrocitinib. These innovative therapies offer rapid symptom relief and effectively address the unmet medical needs of patients suffering from atopic dermatitis, positioning themselves as essential treatment options. Pharmaceutical companies are anticipated to prioritize the development and marketing of JAK inhibitors, capitalizing on their efficacy and favorable safety profiles. As awareness of these therapies expands, they are expected to dominate the treatment landscape, shaping the future of the atopic dermatitis market and enhancing patient outcomes.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Regulatory Analysis
Global Atopic Dermatitis Drugs Market Size by Product Type & CAGR (2025-2032)
- Market Overview
- Biologics
- Others
Global Atopic Dermatitis Drugs Market Size by Drug Class & CAGR (2025-2032)
- Market Overview
- Corticosteroids
- Calcineurin Inhibitors
- PDE4 Inhibitors
- Biologics
- Others
Global Atopic Dermatitis Drugs Market Size by Therapy & CAGR (2025-2032)
- Market Overview
- Photo Therapy
- Directed Therapy
Global Atopic Dermatitis Drugs Market Size by Route of Administration & CAGR (2025-2032)
- Market Overview
- Topical
- Parenteral
- Oral
Global Atopic Dermatitis Drugs Market Size by Distribution & CAGR (2025-2032)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Other Pharmacies
Global Atopic Dermatitis Drugs Market Size & CAGR (2025-2032)
- North America (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
- Europe (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
- Brazil
- Rest of Latin America
- Middle East & Africa (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allergan plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Incyte Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Galderma S.A. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Leo Pharma A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Almirall, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
